ClinicalTrials.gg
TerminatedNCT01026090Updated Aug 6, 2014

Dronedarone Pattern of Use in Patients Scheduled for Elective Cardioversion (ELECTRA)

A Phase 4 interventional study of Dronedarone and Placebo (for dronedarone) in Atrial Fibrillation, sponsored by Sanofi. Terminated at 43 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-08-06.

Sponsored by Sanofi · Phase 4, Interventional, and Treatment

Why this study was terminated
'Sponsor decision following recruitment issues, not related to any safety concerns in the study

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
292
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 26 studies testing dronedarone in Atrial Fibrillation — 2 open to participants now, 2 under way, none of them phase 3. Dronedarone · Atrial Fibrillation.

Enrollment
9th of 26
292 · median 164
Started
2009
the only one that year
Phase 4
11 of 26
2 open now
Registered
6th of 26
by date
Lead sponsor
13 of 26
Sanofi

Among the 26 studies testing dronedarone in Atrial Fibrillation, this one is the 9th largest by enrollment, is the only one that started in 2009, is one of 11 in phase 4, and was the 6th registered.

Atrial Fibrillation

4,011 studies on the registry are indexed under Atrial Fibrillation; 960 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

2 of the 26 studies testing dronedarone in Atrial Fibrillation are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About dronedarone

Dronedarone: first FDA approval 2009 (MULTAQ), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing dronedarone in Atrial Fibrillation, or all of them as a file.
02

Study summary

Primary Objective:

To determine whether daily administration of dronedarone started 5-7 days before cardioversion is superior to dronedarone started only after cardioversion with respect to the absence of symptomatic, ECG confirmed, atrial fibrillation (AF) recurrence over 6 months in adult patients with persistent AF, for whom cardioversion is clinically indicated and planned to reduce symptoms and antiarrhythmic treatment is clinically indicated to reduce the risk of cardiovascular hospitalization due to AF.

Secondary Objectives:

Main Secondary :

  • To assess the number of symptomatic AF recurrences/patient/6 months with and without ECG confirmation;
  • To assess characteristics of symptomatic AF recurrence in the two treatment arms (frequency, duration of episodes, type, number, and severity of AF symptoms per patient);
  • To compare the rates of early recurrences of AF between the two treatment strategies;

Other secondary:

  • To assess whether there is a difference in proportion of patients with symptomatic AF recurrences (with and without ECG confirmation) between the two treatment strategies;
  • To assess whether there is a difference in number of electrical cardioversions per patient between the two treatment strategies;
  • To assess the impact of the two strategies on number of shocks, cumulative amount of energy delivered, shock failure, and immediate success of cardioversion;
  • To assess whether there is a difference in rate of cardiovascular (CV) hospitalizations and length of hospital stay between the two treatment strategies;
  • To assess whether there is a difference in quality of life between the two treatment strategies.
Read the detailed description

The study period of approximatively 6 months consisted in:

  • Double-blind treatment period (placebo or dronedarone) for 5-7 days prior to cardioversion;
  • Electrical cardioversion;
  • Open-label treatment period with dronedarone for 6 months after cardioversion.
03

Conditions studied

  • Atrial Fibrillation

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients with persistent AF (current episode at the screening visit >72 hrs and \<12 month duration), for whom cardioversion was clinically indicated and planned to reduce symptoms and antiarrhythmic treatment was clinically indicated to reduce the risk of cardiovascular hospitalization due to AF.

Exclusion criteria

Exclusion criteria:

  • Severe congestive heart failure ( Class IV) and other unstable hemodynamic conditions;
  • Bradycardia \<50 bpm;
  • Bazett interval ≥500 ms;
  • Second- or third- degree atrio-ventricular (AV) block, or sick sinus syndrome (except when used in conjunction with a functioning pacemaker);
  • Severe hepatic impairment;
  • Pregnancy and lactation;
  • History of reactions to dronedarone or any of its or component of the container.

Concomitant drugs:

  • Antiarrhythmic drugs (AADs) other than dronedarone should not be administered during the study and should be withdrawn for at least five plasma half-lives prior to the first study drug administration;
  • Dronedarone should not be co-administered with strong inhibitors;
  • Dronedarone should not be co-administered with drugs inducing torsades de pointes.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
292 participants (actual)

Study arms

  • Experimental
    Dronedarone pre-cardioversion

    Dronedarone 400 mg twice a day for 5-7 days prior to cardioversion, then dronedarone 400 mg twice a day for 6 months after cardioversion

    Drug: Dronedarone

  • Placebo comparator
    Placebo pre-cardioversion

    Placebo (for dronedarone) twice a day for 5-7 days prior to cardioversion, then dronedarone 400 mg twice a day for 6 months after cardioversion

    Drug: Dronedarone · Drug: Placebo (for dronedarone)

Interventions

  • Film-coated tablet Oral administration under fed conditions (during breakfast and dinner)

    Also known as: MULTAQ, SR33589

  • DrugPlacebo (for dronedarone)

    film-coated tablet strictly identical in appearance Oral administration under fed conditions (during breakfast and dinner)

06

What researchers measure

Primary outcomes

  1. Proportion of participants with at least one symptomatic, ECG confirmed, AF recurrence

    Time frame: 6 months from initial cardioversion

Secondary outcomes

  1. Number of Symptomatic AF Recurrences/Patient/6 Months (With or Without ECG Confirmation)

    Time frame: up to 6 months from initial cardioversion

  2. Characteristics of Symptomatic AF Recurrence (Frequency, Duration of Episodes, Type, Number, and Severity of AF Symptoms)

    Time frame: up to 6 months from initial cardioversion

  3. Proportion of Participants With Early Recurrence of AF (i.e. From 5 Minutes to to 7 Days Following Cardioversion)

    Time frame: up to 7 days following initial cardioversion

  4. Proportion of Participants With Symptomatic AF Recurrences (With or Without ECG Confirmation)

    Time frame: up to 6 months from initial cardioversion

  5. Number of Electrical Cardioversions Per Patient

    Time frame: up to 6 months from intial cardioversion

  6. Number of Shocks Required During Initial Cardioversion

    Time frame: during the initial cardioversion

  7. Cumulative Amount of Energy Delivered and Shock Failure

    Time frame: during the initial cardioversion

  8. Proportion of Participants With Immediate Recurrence of AF (From 5 Seconds to 5 Minutes After Electrical Shock)

    Time frame: during the initial cardioversion

  9. Number of CV Hospitalizations

    Time frame: up to 6 months from initial cardioversion

  10. Quality of Life, as Measured by Atrial Fibrillation Severity Scale (AFSS) and Atrial Fibrillation Effect on Quality of Life (AFEQT) Questionnaires

    Time frame: Baseline and 6 months after initial cardioversion

07

Study locations

43 sites
  • Investigational Site Number 1240033
    Abbotsford, V2S3N5, Canada
  • Investigational Site Number 1240026
    Barrie, L4M4S5, Canada
  • Investigational Site Number 1240050
    Calgary, T2E7C5, Canada
  • Investigational Site Number 1240010
    Cambridge, N1R6V6, Canada
  • Investigational Site Number 1240049
    Edmonton, T5H4B9, Canada
  • Investigational Site Number 1240005
    Granby, J2G1T7, Canada
  • Investigational Site Number 1240001
    Greenfield Park, J4V2G8, Canada
  • Investigational Site Number 1240046
    Grimsby, L3M 1P3, Canada
  • Investigational Site Number 1240040
    Hamilton, L8L 2X2, Canada
  • Investigational Site Number 1240037
    Hamilton, L8N 3Z5, Canada
  • Investigational Site Number 1240044
    Kingston, K7L2V7, Canada
  • Investigational Site Number 1240029
    Kitchener, N2N2A8, Canada
  • Investigational Site Number 1240013
    Laval, H7S2M5, Canada
  • Investigational Site Number 1240043
    Levis, G6V3Z1, Canada
  • Investigational Site Number 1240038
    Maple Ridge, V2X5Z6, Canada
  • Investigational Site Number 1240023
    Montreal, H1T1C8, Canada
  • Investigational Site Number 1240006
    Montreal, H3G 1A4, Canada
  • Investigational Site Number 1240008
    Montreal, H4J1C5, Canada
  • Investigational Site Number 1240018
    Newmarket, L3Y8C3, Canada
  • Investigational Site Number 1240012
    Niagara Falls, L2E7H1, Canada
  • Investigational Site Number 1240020
    North York, M2J1W8, Canada
  • Investigational Site Number 1240015
    Oshawa, L1J2J9, Canada
  • Investigational Site Number 1240036
    Oshawa, Canada
  • Investigational Site Number 1240024
    Ottawa, K1Y4W7, Canada
  • Investigational Site Number 1240032
    Ottawa, K2G3M8, Canada
  • Investigational Site Number 1240056
    Red Deer, T4N4E7, Canada
  • Investigational Site Number 1240053
    Saskatoon, S7N0W8, Canada
  • Investigational Site Number 1240016
    Scarborough, M1E5E9, Canada
  • Investigational Site Number 1240027
    Sherbrooke, J1H 5N4, Canada
  • Investigational Site Number 1240003
    St-Charles Borromee, J6E6J2, Canada
  • Investigational Site Number 1240007
    St-Georges, G5Y 4T8, Canada
  • Investigational Site Number 1240041
    St. John, E2L 4L2, Canada
  • Investigational Site Number 1240002
    Ste-Foy, G1V4G5, Canada
  • Investigational Site Number 1240021
    Sudbury, P3C5K7, Canada
  • Investigational Site Number 1240039
    Sudbury, P3E2N8, Canada
  • Investigational Site Number 1240025
    Toronto, M4N3M5, Canada
  • Investigational Site Number 1240011
    Toronto, M5C 2T2, Canada
  • Investigational Site Number 1240019
    Toronto, M5G2C4, Canada
  • Investigational Site Number 1240009
    Trois-Rivières, G8Z 4K4, Canada
  • Investigational Site Number 1240047
    Vancouver, V5Z1M6, Canada
  • Investigational Site Number 1240035
    Victoria, V8R4R2, Canada
  • Investigational Site Number 1240014
    Willowdale, M2K2W2, Canada
  • Investigational Site Number 1240051
    Windsor, N8X3N9, Canada
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2009, a primary completion of Dec 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2009
First posted
Dec 4, 2009
Start
Nov 2009
Primary completionActual
Dec 2011
CompletionActual
Dec 2011
Last update
Aug 6, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01026090
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Dec 4, 2009
Start date
Nov 2009
Primary completion
Dec 2011
Completion
Dec 2011
Last update
Aug 6, 2014

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dronedarone

Start the discussion